New combo tackles resistant gut tumors in early trial

NCT ID NCT05245968

First seen Jan 28, 2026 · Last updated May 06, 2026 · Updated 17 times

Summary

This early-phase study tests a new drug (TAS-116) combined with imatinib in people with advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib alone. About 78 participants will receive different treatments to find the safest dose and see if the combo can shrink tumors or slow their growth. The study also compares the combo to TAS-116 alone or sunitinib alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alfred Health

    Melbourne, Australia

  • Beijing Cancer Hospital

    Beijing, China

  • Flinders Medical Center

    Adelaide, Australia

  • Fudan University, Shanghai Cancer Center

    Shanghai, China

  • Hokkaido University Hospital

    Hokkaido, Japan

  • Kaohsiung Medical University Hospital

    Kaohsiung City, Taiwan

  • Kumamoto University Hospital

    Kumamoto, Japan

  • Linkou Chang Gung Memorial Hospital

    Linkou District, Taiwan

  • National Cancer Center Hospital

    Tokyo, Japan

  • National Cancer Center Hospital East

    Chiba, Japan

  • National University Cancer Institute

    Singapore, Singapore

  • Osaka University Hospital

    Osaka, Japan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • The Cancer Institute Hospital of JFCR

    Tokyo, Japan

Conditions

Explore the condition pages connected to this study.